{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rifapentine&page=2", "query": { "intervention": "rifapentine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rifapentine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T08:57:36.547Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03510468", "title": "Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Tenofovir alafenamide", "type": "DRUG" }, { "name": "Rifapentine", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2018-06-12", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03510468" }, { "nct_id": "NCT00164450", "title": "TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tuberculosis" ], "interventions": [ { "name": "Isoniazid", "type": "DRUG" }, { "name": "Rifapentine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 158, "start_date": "2005-09", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00164450" }, { "nct_id": "NCT04272242", "title": "Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "LTBI" ], "interventions": [ { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Antiretroviral Therapy (ART)", "type": "DRUG" }, { "name": "Pyridoxine (Vitamin B6)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2021-02-27", "completion_date": "2021-12-27", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 2, "location_summary": "San Francisco, California • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04272242" }, { "nct_id": "NCT03886701", "title": "Doravirine, Rifapentine and Isoniazid Interaction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Latent Tuberculosis", "Human Immunodeficiency Virus", "Rifamycins Causing Adverse Effects in Therapeutic Use", "Drug Interaction Potentiation" ], "interventions": [ { "name": "Doravirine (DOR)", "type": "DRUG" }, { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Walter K. Kraft", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2019-04-22", "completion_date": "2019-05-20", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886701" }, { "nct_id": "NCT00694629", "title": "TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Tuberculosis" ], "interventions": [ { "name": "rifapentine", "type": "DRUG" }, { "name": "rifapentine 10 mg/kg", "type": "DRUG" }, { "name": "rifapentine 15 mg/kg", "type": "DRUG" }, { "name": "rifapentine 20 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 334, "start_date": "2008-12", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00694629" }, { "nct_id": "NCT01404312", "title": "Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberculosis", "HIV Infections" ], "interventions": [ { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine (Vitamin B6)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 3000, "start_date": "2012-05-23", "completion_date": "2017-11-14", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • San Diego, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01404312" }, { "nct_id": "NCT01582711", "title": "Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Latent Tuberculosis Infection" ], "interventions": [ { "name": "Self Administered Therapy (SAT)", "type": "BEHAVIORAL" }, { "name": "SMS reminders", "type": "BEHAVIORAL" }, { "name": "isoniazid and rifapentine", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1002, "start_date": "2012-09", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2025-03-13", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 9, "location_summary": "San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01582711" }, { "nct_id": "NCT02410772", "title": "TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberculosis" ], "interventions": [ { "name": "rifapentine", "type": "DRUG" }, { "name": "rifapentine and moxifloxacin", "type": "DRUG" }, { "name": "control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 2516, "start_date": "2016-01-25", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 5, "location_summary": "San Francisco, California • New York, New York • Fort Worth, Texas + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Fort Worth", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02410772" }, { "nct_id": "NCT00023335", "title": "TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Tuberculosis" ], "interventions": [ { "name": "Rifapentine", "type": "DRUG" }, { "name": "Isoniazid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Centers for Disease Control and Prevention", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "1995-04", "completion_date": "2001-03", "has_results": false, "last_update_posted_date": "2005-09-05", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 20, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023335" }, { "nct_id": "NCT04551573", "title": "A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Tuberculosis", "Hiv" ], "interventions": [ { "name": "Rifapentine daily", "type": "DRUG" }, { "name": "Rifapentine weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-05", "completion_date": "2021-11", "has_results": false, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-09-27T08:57:36.547Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551573" } ] }